Sheba Medical Center and Tel Aviv Sourasky Medical Center-Ichilov have joined an international clinical trial for AccuLine’s AI system designed to assess heart attack risk by detecting coronary artery disease noninvasively. The trial will involve about 2,000 patients across approximately 20 medical centers, primarily in the United States, as part of efforts to gain FDA clearance for the CORA system, which rapidly evaluates a patient’s risk using electrocardiogram data, blood oxygen levels, and other clinical factors without the need for invasive procedures or radiation. Both hospitals are notable for their ongoing integration of AI technologies, with Sheba focusing on emergency and triage tools and Ichilov collaborating with AWS on clinical data applications.
AccuLine: AccuLine is a Petah Tikva-based Israeli medtech startup developing the CORA AI platform for noninvasive coronary artery disease risk assessment. The system integrates electrocardiogram, oxygen saturation, respiration, and patient clinical data to generate rapid risk scores. AccuLine is leading an international clinical trial at multiple centers, including Sheba and Ichilov, toward FDA clearance.
Moshe Barel: Moshe Barel is the CEO and co-founder of AccuLine with extensive experience leading medtech programs in clinical development. He advocates for innovations addressing challenges in medical device adoption. In the news, he explained how CORA could empower community physicians to identify at-risk patients noninvasively and reduce unnecessary procedures.
Sheba Medical Center: Sheba Medical Center is Israel’s largest medical center, renowned for its ARC Innovation Center that advances AI-driven healthcare solutions. It has recently gained approval for AI-based psychiatric triage tools and launched ambient AI platforms for emergency departments. Sheba is participating in AccuLine’s international clinical trial to evaluate the CORA AI system for noninvasive coronary artery disease detection.
Professor Yaron Arbel: Professor Yaron Arbel is a senior interventional cardiologist and director of the Cardiovascular Research Center at Tel Aviv Sourasky Medical Center-Ichilov. He focuses on advanced cardiology treatments and research initiatives. He noted that the clinical trial will evaluate the role of AccuLine’s technology in diagnosing patients with suspected coronary heart disease.
Professor Israel Barbash: Professor Israel Barbash directs the Interventional Cardiology Unit at Sheba Medical Center and specializes in coronary and structural interventional cardiology. He contributes to editorial boards and research on cardiac innovations. In this news, he highlighted the importance of AI tools for enabling faster and more accurate early diagnoses.
Tel Aviv Sourasky Medical Center-Ichilov: Tel Aviv Sourasky Medical Center, known as Ichilov Hospital, is a leading university-affiliated facility specializing in advanced cardiology and research. It recently extended a strategic partnership with AWS to develop AI applications using clinical data. Ichilov has joined the international clinical trial for AccuLine’s CORA technology to assess its diagnostic potential for coronary heart disease.
Trial Objective: The clinical trial validates AccuLine’s CORA AI system for detecting coronary artery disease noninvasively as part of FDA clearance efforts.
CORA Functionality: CORA processes electrocardiogram, blood oxygen saturation, respiration rate, along with clinical information and risk factors to produce a risk score quickly without radiation or exertion.
Hospital AI Momentum: Both Sheba and Ichilov actively pursue AI integrations, with Sheba advancing emergency and triage tools and Ichilov collaborating with AWS on clinical data AI.